Guillain-Barré syndrome (GBS) has no cure, but two main treatments can significantly reduce the severity of the illness and speed recovery: immunoglobulin therapy given through an IV, and a blood-filtering procedure called plasma exchange. About 60% of adults recover full motor strength within a year of diagnosis, though treatment needs to start early for the best results.
The Two Main Treatments
Both frontline treatments work by calming the immune system’s mistaken attack on the nerves. In GBS, the body’s immune defenses target the protective coating around peripheral nerves, causing progressive weakness that can spread from the legs upward. Treatment aims to interrupt that process as quickly as possible.
Immunoglobulin therapy (IVIG) involves receiving a concentrated dose of healthy antibodies collected from blood donors, delivered through an IV over several days. These donated antibodies help neutralize the harmful ones your body is producing. A meta-analysis published in Neurology, pooling data from six studies with over 340 patients, found that IVIG was more effective than plasma exchange at reducing disability scores.
Plasma exchange (also called plasmapheresis) physically removes the harmful antibodies from your blood. Your blood is drawn out, the liquid portion containing the damaging antibodies is separated and replaced, and the cleaned blood is returned. This is typically done several times over one to two weeks. It remains an effective option, particularly when IVIG isn’t available or isn’t tolerated.
The two treatments are not combined. Using both together has not shown added benefit over either one alone. Your medical team will choose based on availability, your overall health, and how quickly the disease is progressing.
Why Steroids Don’t Work for GBS
Corticosteroids are a go-to treatment for many autoimmune conditions, so it’s reasonable to wonder why they aren’t used here. A Cochrane review of multiple trials found that corticosteroids given alone do not speed recovery or improve long-term outcomes. Oral steroids actually performed worse: across four trials involving 120 participants, patients given oral corticosteroids showed significantly less improvement at four weeks than those who received no steroids at all. Intravenous corticosteroids fared slightly better but still showed no meaningful benefit.
The leading explanation is that steroids may have a damaging effect on muscle tissue that cancels out whatever benefit they offer by reducing nerve inflammation. Steroid use in GBS also increased rates of diabetes requiring insulin. For these reasons, corticosteroids are not part of standard GBS treatment.
Hospital Monitoring and Supportive Care
GBS can affect more than just limb strength. It can weaken the muscles you use to breathe and disrupt the automatic systems that control heart rate and blood pressure. This is why people with GBS are closely monitored in the hospital, often in an intensive care unit.
Doctors track your breathing capacity with repeated measurements of how much air your lungs can move. If those numbers drop below a safe threshold, mechanical ventilation (a breathing machine) may be needed temporarily. Patients with any signs of autonomic dysfunction, such as wild swings in blood pressure or an irregular heartbeat, require continuous cardiac monitoring.
Immobility brings its own risks. People who can’t move their legs are vulnerable to blood clots. One retrospective study found that the risk of developing a deep vein thrombosis dropped from roughly 30% to 6% with the use of blood-thinning medication, though specific guidelines for GBS patients are still being refined.
Managing Pain During GBS
Pain is one of the most underappreciated parts of GBS. Many people expect only weakness, but nerve pain can be severe, sometimes described as burning, aching, or shooting sensations that are worst in the back, legs, and arms. This pain can be intense enough to limit participation in physical therapy.
Because the pain originates from damaged nerves rather than injured tissue, standard painkillers like ibuprofen are often insufficient. Medications originally developed for seizures, particularly gabapentin and carbamazepine, have shown positive results in small trials for nerve pain in GBS. Traditional pain medications like opioids have been used historically but carry significant side effects, which has pushed treatment toward these nerve-targeted alternatives.
Rehabilitation: What Recovery Looks Like
Physical therapy begins at the bedside, often before you’re strong enough to sit up on your own. In the earliest phase, therapists focus on gently moving your joints through their full range of motion to prevent stiffness and contractures from prolonged bed rest. Sessions may start daily but can be scaled back to every other day if pain and fatigue are too severe.
As strength begins to return, often within a few weeks of starting immunotherapy, the focus shifts to functional goals: sitting upright, standing with support, and eventually walking. Body weight support treadmill training, where a harness takes some of your weight while you practice walking, is one approach used when leg weakness is still significant.
After hospital discharge, outpatient physical therapy continues the progression. In one documented case, a patient went from needing full assistance to walking community distances of up to a mile with a cane within a month of going home. Over the following months, she progressed to walking independently. That trajectory is realistic for many patients, though the timeline varies widely depending on how severe the initial illness was.
Long-Term Recovery and What to Expect
Recovery from GBS is measured in months, not weeks. The pattern is typically a rapid worsening phase lasting two to four weeks, a plateau where symptoms hold steady, and then a gradual recovery phase that can stretch over six months to two years.
According to Mayo Clinic data, about 60% of adults recover full motor strength by one year after diagnosis. That’s encouraging, but it also means a substantial number of people carry some lasting effects. Between 5% and 10% of patients experience very delayed and incomplete recovery, potentially dealing with persistent weakness, fatigue, or altered sensation long-term. Low nerve signal amplitudes measured early in the disease have been associated with longer and potentially incomplete recovery, giving doctors an early indicator of how challenging the road ahead may be.
Fatigue is one of the most common lingering complaints, even among people whose strength tests return to normal. Many GBS survivors describe a level of exhaustion that goes beyond what their visible recovery would suggest, and it can persist for years. Residual tingling or numbness in the hands and feet is also common, though for most people it becomes manageable over time.